貝瑞基因(000710.SZ)擬轉讓涉房業務控股子公司股權
格隆匯12月9日丨貝瑞基因(000710.SZ)公佈,公司擬與福州漢興景和投資有限公司簽署《股權轉讓協議》,公司擬將持有的控股子公司福建貝瑞和康健康管理有限公司70%股權(對應註冊資本人民幣8400萬元)轉讓給福州漢興景和投資有限公司(目前持有福建貝瑞和康健康管理有限公司30%股權),股權轉讓價款為1.5億元。本次交易完成後,公司將不再持有福建貝瑞和康健康管理有限公司股權,合併報表範圍將發生變化,公司獲得的股權轉讓價款將用於補充流動資金,為公司發展主業提供資金支持。
福建貝瑞和康健康管理有限公司的主營業務中含有房地產開發及銷售,此部分業務與公司主營業務關聯度不高,並且對公司非公開發行股票相關工作產生障礙,本次交易有利於公司進一步整合資源並將更多資源聚焦在主營業務領域,提高公司資產運營效率,同時推進公司非公開發行股票相關進度,將對公司產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.